Catabasis Pharmaceuticals (Cambridge, MA) a clinical-stage biopharmaceutical company focused on fatty acid conjugated compounds for severe hypertriglyceridemia, diabetes, inflammatory and metabolic diseases, closed a $8M Series A financing bringing total round to $47.6M. Participants include SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures.

Verona Pharma (United Kingdom) a clinical-stage biotechnology company focused on chronic respiratory diseases and inflammation for asthma, COPD, cough, and rhinitis, closed a $11.5M Series A financing. Participants include Henderson Global Investors.

Aratana Therapeutics (Kansas City, KS) a clinical-stage animal health company focused on pain, cancer, inflammation, cachexia and frailty, closed a $15.5M Series B financing. Participants include Ewing Marion Kauffman Foundation, MPM Capital, Cultivian Ventures and Avalon Ventures.

TopiVert (United Kingdom) a development-stage pharmaceutical company focused on topical medicines for inflammatory diseases of the eye and gut, closed a $12.5M Series A financing. Participants include Imperial Innovations Group and SV Life Sciences.

Atox Bio (Israel) a clinical-stage biotechnology company focused on small molecules for the treatment of severe bacterial infections, sepsis, necrotizing soft tissue infections and intra-abdominal infections, closed a $3.25M Series A financing. Participants include Esperante.

Portola Pharmaceuticals (South San Francisco, CA) a clinical-stage small moelcule company focused on acute and chronic cardiovascular and autoimmune and inflammatory diseases, closed an $89M Series E financing. Participants included Temasek, Eastern Capital Limited, D.E. Shaw, Adage Capital Management, BBT Capital Management, Janus Capital Group and Pac-Link BioVentures.

arGEN-X (Netherlands) a preclinical-stage biopharmaceutical company focused on a monoclonal antibody platform for autoimmunity, inflammation and oncology, closed a $37M Series B financing. Participants include Orbimed, Seventure, Credit Agricole Private Equity, Forbion Capital Partners, Life Science Partners, BioGeneration Ventures, Erasmus MC Biomedical Fund, Thuja Capital Healthcare and VIB.

Karyopharm Therapeutics (Natick, MA) a preclinical-stage small molecule company focusing on the treatment of cancer and inflammation, closed a $10M Series A financing, bringing the total round to $30M. Participants include Chione.

SARcode (Brisbane, CA) a clinical-stage biopharmaceutical company focused on chronic T-cell mediated inflammation in ophthalmic and dermatologic disease, closed a $44M Series B financing. Participants include Sofinnova Ventures, Rho Ventures, Alta Partners and Clarus Venture Partners.
Thanx for your patience as we catch-up.

Zymeworks (Canada) a preclinical-stage biopharma focused on protein-based therapeutics for oncology and inflammatory disease, closed a $8.1M Series D financing. Participants include CTI Life Sciences Fund and Advanced Biotechnologies Venture Fund.
Thanx for your patience as we catch-up.

Theraclone Sciences (Seattle, WA) a preclinical-stage biopharmaceutical company focused on monoclonal antibodies for infectious disease and inflammation, closed a $10.6M Series B, bringing the total round to $41M. Participants include Arch Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures and Zenyaku Kogyo.

Constellation Pharmaceuticals (Cambridge, MA) a development-stage biopharma focused on small molecule therapeutics against chromatin-based targets to treat cancer and inflammatory disorders, closed a $15M Series B financing bringing the total round to $37M. Participants include S.R. One, Altitude Life Science Ventures, Third Rock Ventures, The Column Group and Venrock.
The 2Q11 OnBioVC Trend Analysis will be [...]

Shield Therapeutics (United Kingdom) a clinical-stage pharmaceutical company focused on inflammatory bowel disease, closed a$12M Series A financing. Participants include Inventages Venture Capital.